,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2014-07-16 08:35:00,St. Jude Medical Inc. ( STJ ) posted a 6.25% rise in adjusted net earnings per share to $1.02 for the second quarter of 2014 from 96 cents in the year-ago quarter.,0.9577548503875732,0.024585111066699028,0.01765998639166355,positive,0.9331697225570679
1,2014-07-16 08:35:00,"With this, the St. Paul, MN-based medical device maker's earnings per share beat the Zacks Consensus Estimate by a couple of cents and outdid the company's own guidance of 99 cents to $1.01 for the quarter.",0.9417859315872192,0.03746061772108078,0.02075335383415222,positive,0.9043253064155579
2,2014-07-16 08:35:00,Net adjusted earnings rose 7.3% to $295 million from $275 million in the 2013-second quarter.,0.9586611390113831,0.02383098565042019,0.017507927492260933,positive,0.9348301291465759
3,2014-07-16 08:35:00,"Reported earnings were $270 million or 93 cents per share in the quarter, compared with $115 million or 40 cents per share in the comparable quarter of 2013.",0.3480794429779053,0.6135278344154358,0.03839271888136864,negative,-0.2654483914375305
4,2014-07-16 08:35:00,"Revenues grew about 3.2% (both in reported and constant-currency) to $1,448 million for the quarter, which surpassed the Zacks Consensus Estimate of $1,436 million but lied within the company's own guided range of $1,380 to $1,460 million.",0.9562565684318542,0.018206385895609856,0.025536946952342987,positive,0.9380502104759216
5,2014-07-16 08:35:00,Favorable foreign currency translation boosted revenues by roughly $4 million in the second quarter.,0.9565429091453552,0.02119658887386322,0.022260526195168495,positive,0.9353463053703308
6,2014-07-16 08:35:00,"Revenues from the international market rose 6.1% to $779 million, accounting for 53.8% of total revenues.",0.9530046582221985,0.017963841557502747,0.02903146483004093,positive,0.9350408315658569
7,2014-07-16 08:35:00,"However, revenues from the U.S. were flat at $669 million compared with the year ago level, accounting for 46.2% of total revenues.",0.018281513825058937,0.9578068256378174,0.0239117369055748,negative,-0.939525306224823
8,2014-07-16 08:35:00,"In the Cardiac Rhythm Management (CRM) division, revenues went up roughly 2.0% (both in reported and constant-currency) to $733 million.",0.9554115533828735,0.018603792414069176,0.025984706357121468,positive,0.9368077516555786
9,2014-07-16 08:35:00,U.S. revenues upped 0.5% to $382 million while international revenues zoomed 3.8% to $351 million in the quarter.,0.9509414434432983,0.030336806550621986,0.018721770495176315,positive,0.9206046462059021
10,2014-07-16 08:35:00,"In the CRM division, implantable cardiac defibrillator (ICD) revenues escalated 1.8% (1% in constant-currency) to $462 million.",0.9491385221481323,0.03234439343214035,0.018517084419727325,positive,0.9167941212654114
11,2014-07-16 08:35:00,"Meanwhile, pacemaker revenues scaled up 2.65% to $271 million compared with the prior year quarter.",0.9517093300819397,0.03165782615542412,0.016632774844765663,positive,0.9200515151023865
12,2014-07-16 08:35:00,"At constant-currency, pacemaker revenues rose by 3% in the quarter.",0.9579682350158691,0.018503807485103607,0.02352791838347912,positive,0.9394644498825073
13,2014-07-16 08:35:00,"In the Atrial Fibrillation (AF) division, revenues scaled up 8.4% to $257 million, while at constant currency it increased 8% over the second quarter of 2013. International revenues grew 9.7% to $159 million while U.S. revenues rose 6.5% to $98 million in the quarter.",0.9518130421638489,0.016235552728176117,0.03195136785507202,positive,0.9355775117874146
14,2014-07-16 08:35:00,"In the Cardiovascular division, revenues went up 3.2% to $351 million in the quarter and roughly 3% at constant-currency.",0.9542155265808105,0.020255189388990402,0.02552933059632778,positive,0.9339603185653687
15,2014-07-16 08:35:00,Revenues from the international market rose 4.5% to $233 million and from the U.S. market inched up 0.9% to $118 million.,0.9550216197967529,0.02035876363515854,0.024619633331894875,positive,0.9346628785133362
16,2014-07-16 08:35:00,"In the cardiovascular division, vascular product revenues edged up roughly 1.0% to $180 million.",0.9557481408119202,0.021470099687576294,0.022781826555728912,positive,0.9342780113220215
17,2014-07-16 08:35:00,"Meanwhile, structural heart product revenues increased 6.0% to $171 million for the quarter.",0.9574047327041626,0.017207378521561623,0.025387831032276154,positive,0.9401973485946655
18,2014-07-16 08:35:00,"In the Neuromodulation division, revenues went down nearly 1.0% to $107 million in the second quarter, both on reported and constant-currency bases.",0.017392881214618683,0.972260594367981,0.010346467606723309,negative,-0.9548677206039429
19,2014-07-16 08:35:00,Revenues from the U.S. ebbed 11.0% to $71 million but revenues from the international market improved 29% to $36 million in the 2014-second quarter.,0.9488894939422607,0.029580997303128242,0.02152956835925579,positive,0.9193084836006165
20,2014-07-16 08:35:00,"St. Jude Medical had cash and cash equivalents of $1,580 million as of Jun 28, 2014, up 15.1% from $1,373 million as of Dec 28, 2013.",0.9561129212379456,0.021451439708471298,0.022435562685132027,positive,0.9346615076065063
21,2014-07-16 08:35:00,"Total debt rose 17.5% to $4,206 million as of Jun 28, 2014 compared with $3,580 million as of Dec 28, 2013.",0.9511519074440002,0.02351364679634571,0.025334469974040985,positive,0.9276382327079773
22,2014-07-16 08:35:00,"Consequently, debt-to-capitalization increased 620 basis points to 51.0% from 44.8% as of Dec 28, 2013.",0.9595123529434204,0.02040896937251091,0.020078683272004128,positive,0.939103364944458
23,2014-07-16 08:35:00,"For the third quarter of 2014, St. Jude Medical expects revenues in the range of $1,315 to $1,395 million while the company anticipates adjusted net earnings per share to lie between 95 and 97 cents for the quarter.",0.08054643869400024,0.017236415296792984,0.9022170901298523,neutral,0.06331002712249756
24,2014-07-16 08:35:00,"The current Zacks Consensus Estimates for earnings per share and revenues for the quarter are pegged at 96 cents and $1,396 million.",0.02583080343902111,0.026329495012760162,0.9478397369384766,neutral,-0.0004986915737390518
25,2014-07-16 08:35:00,"For full year 2014, St. Jude Medical upgraded its revenues guidance to the range of $5,640 to $5,760 million from the prior outlook of $5,610 to $5,760 million.",0.9272284507751465,0.019717944785952568,0.05305350944399834,positive,0.90751051902771
26,2014-07-16 08:35:00,The company has also upgraded its adjusted earnings per share guidance to $3.96 to $4.01 from the prior range of $3.95-$4.00.,0.9456747770309448,0.01953512616455555,0.03479019179940224,positive,0.9261396527290344
27,2014-07-16 08:35:00,"The current Zacks Consensus Estimates for earnings per share and revenues for the year are pegged at $3.98 and $5,701 million.",0.026819759979844093,0.027950769290328026,0.9452294707298279,neutral,-0.0011310093104839325
28,2014-07-16 08:35:00,"We are impressed with St. Jude Medical's second quarter results, which topped estimates on both earnings and revenues fronts.",0.9387123584747314,0.01705305650830269,0.04423460364341736,positive,0.9216592907905579
29,2014-07-16 08:35:00,"Moreover, the company's upgraded earnings and revenues guidance is encouraging.",0.9516851902008057,0.016935933381319046,0.03137898072600365,positive,0.9347492456436157
30,2014-07-16 08:35:00,"We are optimistic about the company's recent acquisition of privately-held CardioMEMS, Inc. at the beginning of last month.",0.6600337028503418,0.011343480087816715,0.32862284779548645,positive,0.6486902236938477
31,2014-07-16 08:35:00,"With the closure of the CardioMEMS acquisition, St. Jude Medical expects accelerated growth in its cardiovascular segment.",0.9400908350944519,0.014105208218097687,0.045804012566804886,positive,0.9259856343269348
32,2014-07-16 08:35:00,"Currently, St. Jude carries a Zacks Rank #2 (Buy).",0.2735719382762909,0.022090885788202286,0.7043371796607971,neutral,0.2514810562133789
33,2014-07-16 08:35:00,"Other stocks in the medical products industry that are also worth considering include Hospira Inc. ( HSP ), OraSure Technologies, Inc. ( OSUR ), and Wright Medical Group Inc. ( WMGI ).",0.0729667916893959,0.005411243997514248,0.9216219782829285,neutral,0.06755554676055908
34,2014-07-16 08:35:00,All of them sport a Zacks Rank #1 (Strong Buy).,0.41752225160598755,0.02615031786262989,0.5563274025917053,neutral,0.3913719356060028
35,2014-07-16 08:35:00,Want the latest recommendations from Zacks Investment Research?,0.03539300337433815,0.011573811061680317,0.9530332088470459,neutral,0.023819193243980408
36,2014-07-16 08:35:00,"Today, you can download 7 Best Stocks for the Next 30 Days.",0.05069372057914734,0.007019792217761278,0.9422864317893982,neutral,0.04367392882704735
37,2014-07-16 08:35:00,"Click to get this free report

To read this article on Zacks.com click here.",0.020684564486145973,0.03315984085202217,0.9461556077003479,neutral,-0.012475276365876198
38,2014-07-16 08:35:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204561054706573,0.01563790813088417,0.9741575717926025,neutral,-0.005433347076177597
